Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Harrow, Inc. - Common Stock (NQ:HROW)

45.05 -1.60 (-3.44%)
Streaming Delayed Price Updated: 2:18 PM EDT, Jul 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Harrow, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
ImprimisRx Launches Fortisite™ (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulation
From Harrow
Via Business Wire
News headline image
Harrow Announces U.S. FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia
From Harrow
Via Business Wire
News headline image
Harrow Health to Participate in H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
From Harrow Health, Inc.
Via Business Wire
News headline image
Harrow Health Announces Second Quarter 2022 Financial Results
From Harrow Health, Inc.
Via Business Wire
News headline image
Harrow Health to Announce Second Quarter 2022 Financial Results on August 9, 2022
From Harrow Health, Inc.
Via Business Wire
News headline image
Harrow Health Announces Launch of IOPIDINE® 1% and MAXITROL® in the United States
From Harrow Health, Inc.
Via Business Wire
News headline image
Harrow Health Announces First Quarter 2022 Financial Results
From Harrow Health, Inc.
Via Business Wire
News headline image
Melt Pharmaceuticals Announces MELT-210 Top-Line Results of Phase 1 Pharmacokinetics (PK) Study for Procedural Sedation
From Melt Pharmaceuticals, Inc.
Via Business Wire
News headline image
Harrow Health to Participate in B. Riley Securities’ Annual Neuro & Ophthalmology Investor Conference
From Harrow Health, Inc.
Via Business Wire
News headline image
Harrow Health to Announce First Quarter 2022 Financial Results on May 5, 2022
From Harrow Health, Inc.
Via Business Wire
News headline image
Harrow Health Announces Appointments to Its Board of Directors
From Harrow Health, Inc.
Via Business Wire
News headline image
Harrow Health to Announce Fourth Quarter and Year-End 2021 Financial Results on March 10, 2022
From Harrow Health, Inc.
Via Business Wire
News headline image
Harrow Health Announces FDA Acceptance of New Drug Application for AMP-100
From Harrow Health, Inc.
Via Business Wire
News headline image
Harrow Health to Present at Aegis Virtual Conference
From Harrow Health, Inc.
Via Business Wire
News headline image
Harrow Health Publishes Corporate Transparency Report
From Harrow Health, Inc.
Via Business Wire
News headline image
Harrow Health to Participate in H.C. Wainwright BioConnect Conference
From Harrow Health, Inc.
Via Business Wire
News headline image
Melt Pharmaceuticals Submits INDs for MELT‑210 and MELT-400 to FDA
From Melt Pharmaceuticals, Inc.
Via Business Wire
News headline image
Harrow Health Acquires U.S. Commercial Rights to Four Branded Eye Drops
From Harrow Health, Inc.
Via Business Wire
News headline image
Harrow Health Added to the Nasdaq Biotechnology Index
From Harrow Health, Inc.
Via Business Wire
News headline image
Harrow Health Announces Third Quarter 2021 Financial Results
From Harrow Health, Inc.
Via Business Wire
News headline image
Harrow Health to Announce Third Quarter 2021 Financial Results on November 9, 2021
From Harrow Health, Inc.
Via Business Wire
News headline image
Harrow Health Provides $13.5 Million Senior Secured Loan to Melt Pharmaceuticals
From Harrow Health, Inc.
Via Business Wire
News headline image
Harrow Health Acquires Ophthalmic Surgical Drug Candidate From Wakamoto Pharmaceutical Co., Ltd.
From Harrow Health, Inc.
Via Business Wire
News headline image
Harrow Health to Participate in Two Upcoming Virtual Investor Conferences
From Harrow Health, Inc.
Via Business Wire
News headline image
Harrow Health Announces Second Quarter 2021 Financial Results
From Harrow Health, Inc.
Via Business Wire
News headline image
Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sintetica
From Harrow Health, Inc.
Via Business Wire
News headline image
NovaBay Pharmaceuticals Partners with Harrow Health’s ImprimisRx® to Promote Prescription Avenova
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.